Lipase preparation and method thereof

Lipase compositions, particularly enteric-coated non-porcine lipases, effectively treat EPI by enhancing fat absorption and addressing malabsorption symptoms, improving nutritional outcomes in patients with conditions like cystic fibrosis and chronic pancreatitis.

JP2024544390AInactive Publication Date: 2024-11-29FIRST WAVE BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024535835
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-16
Filing Date
2022-12-15
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Exocrine pancreatic insufficiency (EPI) leads to malabsorption and nutritional deficiencies due to pancreatic lipase deficiency, which is common in conditions like cystic fibrosis, chronic pancreatitis, and pancreatic resection, with existing treatments like porcine pancreatic enzyme replacement therapy (PERT) failing to adequately manage severe cases.

Method used

Oral administration of lipase compositions, optionally combined with liquid nutritional formulations, to enhance fat absorption and address malabsorption symptoms such as steatorrhea, abdominal pain, and weight loss, using non-porcine lipases like Adolelipase or pancrelipase, formulated with enteric coatings to protect against stomach acid and deliver lipase to the duodenum.

Benefits of technology

Significantly increases fat absorption, reduces steatorrhea, improves stool morphology, and promotes weight gain, demonstrating efficacy in treating EPI without the need for supplemental proteases, with formulations showing safety and tolerability across various doses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544390000001_ABST
    Figure 2024544390000001_ABST
Patent Text Reader

Abstract

The present invention relates to a method for treating nutritional deficiencies, the method comprising orally administering a lipase composition, optionally in combination with a liquid nutritional preparation, to a patient in need. In certain embodiments, the present invention relates to a method for treating a patient in need of weight gain, the method comprising orally administering a lipase composition, optionally in combination with a liquid nutritional preparation, to a patient in need, the lipase being in a solution or suspension in a culture medium, and the lipase assisting the absorption of one or more fat-soluble vitamins, such as vitamin A, vitamin D, vitamin E, and vitamin K.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions, methods for treating malabsorption, and related treatments with lipase. [Background technology]

[0002] Exocrine pancreatic insufficiency (EPI) can result from disease states such as cystic fibrosis and chronic pancreatitis. The symptomatology of EPI is essentially due to pancreatic lipase deficiency, an enzyme that hydrolyzes triglycerides into monoglycerides and free fatty acids.

[0003] Chronic pancreatitis (CP), the most common cause of EPI, is a prolonged inflammation of the pancreas that alters its normal structure and function, which is associated with EPI in approximately 60% of patients. Cystic fibrosis (CF), another frequent etiology of EPI, is a severe genetic disease associated with chronic morbidity and reduced life span in most affected individuals. Approximately 80-90% of patients with CF develop EPI. In addition, EPI is common after surgical resection of the pancreas, usually as a result of cancer or complications of CP. Other less common etiologies of EPI include gastric surgery, certain intestinal diseases (e.g., severe celiac disease, small bowel resection, and artificial enteral feeding), and pancreatic diseases (e.g., pancreatic trauma, severe acute pancreatitis with pancreatic necrosis, and pancreatic cancer).

[0004] The effect of EPI and other disease states is malabsorption and subsequent nutritional deficiencies.

[0005] Thus, there continues to be a need in the art for pharmaceutical compositions and treatments for treating malabsorption caused by a variety of factors. Summary of the Invention

[0006] In certain embodiments, the present invention is directed to lipase dosage forms, methods of treatment, and methods of manufacture.

[0007] In certain embodiments, the present invention is directed to a method of treating a nutritional deficiency, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0008] In certain embodiments, the present invention is directed to a method for increasing absorption of a fat-soluble vitamin, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0009] In certain embodiments, the present invention is directed to a method of treating a patient in need of weight gain, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0010] In certain embodiments, the present invention is directed to a method of treating steatorrhea, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0011] In certain embodiments, the present invention is directed to a method of treating abdominal pain, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0012] In certain embodiments, the present invention is directed to a method of treating flatulence, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0013] In certain embodiments, the present invention is directed to a method for reducing the number of daily bowel movements, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0014] In certain embodiments, the present invention is directed to a method for reducing stool weight, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0015] In certain embodiments, the present invention is directed to a method of improving stool form, the method comprising orally administering to a patient in need thereof a lipase composition, optionally in combination with a liquid nutritional formulation.

[0016] In certain embodiments, the present invention is directed to a composition comprising a lipase, optionally in combination with a liquid nutritional formulation.

[0017] In certain embodiments, the present invention is directed to processes for making the compositions and dosage forms disclosed herein.

[0018] In certain embodiments, the present invention is directed to a method of treating malabsorption resulting from exocrine pancreatic insufficiency comprising administering a dosage form disclosed herein. In certain embodiments, the insufficiency may be caused by one or more of acute or chronic pancreatitis, cystic fibrosis, pancreatic resection (whether or not associated with cancer, such as pancreatic cancer), age-related, Shwachman-Diamond syndrome, type 1 diabetes, type 2 diabetes, HIV, celiac disease, or inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).

[0019] In certain embodiments, the method comprises delivering lipase to the colon of a patient by orally administering a formulation disclosed herein, in certain embodiments, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% of the lipase is delivered to the colon of the patient. [Brief description of the drawings]

[0020] [Figure 1] FIG. 1 is a schematic diagram of the study of Example 4. [Diagram 2] 1 shows clinical results from Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] The present invention advances the state of the art by providing methods and compositions thereof for treating malabsorption and related disease states.

[0022] In certain embodiments, the present invention is directed to a method of treating a nutritional deficiency, the method comprising orally administering to a patient in need thereof a lipase composition.

[0023] In certain embodiments, the lipase aids in the absorption of one or more of fat, vitamin A, vitamin D, vitamin E, and vitamin K.

[0024] In certain embodiments, the patient has improvement in one or more of weight gain, fatty stools, abdominal pain, bloating, daily bowel movements, stool weight, and stool shape.

[0025] In certain embodiments, the patient experiences a weight gain of at least 2%, or between about 2% and about 12%, in a period selected from 3 months, 6 months, 9 months, or 12 months.

[0026] In certain embodiments, the patient experiences a weight gain of at least 5%, or between about 5% and about 15%, in a period selected from 3 months, 6 months, 9 months, or 12 months.

[0027] In certain embodiments, the patient experiences a weight gain of at least 8%, or between 8% and about 18%, in a period selected from 3 months, 6 months, 9 months, or 12 months.

[0028] In certain embodiments, the patient experiences a weight gain of at least 10%, or between about 10% and about 20%, in a period selected from 3 months, 6 months, 9 months, or 12 months.

[0029] In certain embodiments, the patient experiences a weight gain of at least 12% or about 12% to about 22% in a time period selected from 3 months, 6 months, 9 months, or 12 months. In certain embodiments, the fat absorption coefficient increases by at least 2%, at least 4%, at least 5%, at least 7%, at least 10%, or about 2% to about 15%, or about 4% to about 12%, or about 5% to about 10%, for example, in 15 days, 30 days, or 45 days.

[0030] In certain embodiments, stool weight (g / 72 hr) is reduced by at least 2%, at least 4%, at least 5%, at least 7%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 22%, at least 25%, or by about 2% to about 25%, or by about 5% to about 22%, or by about 10% to about 20%, for example, at 15 days, 30 days, or 45 days.

[0031] In certain embodiments, steatorrhea (g / 24 hr) is reduced by at least 2%, at least 4%, at least 5%, at least 7%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 22%, at least 25%, or by about 2% to about 25%, or by about 5% to about 22%, or by about 10% to about 20%, for example, at 15, 30, or 45 days.

[0032] In certain embodiments, daily stools are reduced by at least 2%, at least 4%, at least 5%, at least 7%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 22%, at least 25%, or by between about 2% and about 25%, or by between about 5% and about 22%, or by between about 10% and about 20%, for example, over 15, 30, or 45 days.

[0033] In certain embodiments, the Bristol score is reduced by at least 2%, at least 4%, at least 5%, at least 7%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 22%, at least 25%, or by between about 2% and about 25%, or by between about 5% and about 22%, or by between about 10% and about 20%, for example, at 15 days, 30 days, or 45 days.

[0034] In certain embodiments, the lipase composition is administered once per day, twice per day, three times per day, or four times per day.

[0035] In certain embodiments, the lipase composition is administered with one or more meals.

[0036] In certain embodiments, the lipase composition is administered for at least 1 day, at least 7 days, at least 1 month, at least 3 months, at least 6 months, at least 9 months, or at least 12 months.

[0037] In certain embodiments, the lipase composition is administered with a liquid nutritional formulation, such as a high-calorie nutritional supplement, such as Ensure®.

[0038] In certain embodiments, the lipase composition is administered simultaneously or sequentially with the liquid nutritional formulation.

[0039] In certain embodiments, the liquid nutritional formula is administered by a feeding tube.

[0040] In certain embodiments, the lipase composition and the liquid nutritional formulation are part of the same composition.

[0041] In certain embodiments, the patient has EPI.

[0042] In certain embodiments, the patient does not have EPI.

[0043] In certain embodiments, the patient is over 60 years of age.

[0044] In certain embodiments, the patient has cancer or acute pancreatitis.

[0045] In certain embodiments, the lipase composition comprises porcine lipase.

[0046] In certain embodiments, the lipase composition comprises a non-porcine lipase.

[0047] In certain embodiments, the lipase composition comprises adorolipase, pancrelipase, liprotamase, or a combination thereof.

[0048] In certain embodiments, the lipase composition comprises an adole lipase.

[0049] In certain embodiments, the present invention is directed to a method of increasing fat absorption, the method comprising orally administering a lipase composition to a patient in need thereof.

[0050] In certain embodiments, the present invention is directed to a method of increasing absorption of a fat-soluble vitamin, the method comprising orally administering a lipase composition to a patient in need thereof.

[0051] In certain embodiments, the present invention is directed to a method for treating a patient in need of weight gain, comprising orally administering a lipase composition to a patient in need thereof. The patient in need of weight gain may be a patient with EPI, borderline EPI, or no EPI. In certain embodiments, the patient in need of weight gain is due to one or more conditions selected from cancer, dementia, dental problems, depression, diabetes, hypercalcemia, hyperthyroidism, hyponatremia, medications, Parkinson's disease, previous stroke or neuropathy, Addison's disease, alcohol use disorder, amyloidosis, celiac disease, Crohn's disease, drug addiction, heart failure, AIDS / HIV, peptic ulcer, prescription drug use, tuberculosis, ulcerative colitis, exercise, and genetic predisposition.

[0052] In certain embodiments, the present invention is directed to a method of treating steatorrhea, the method comprising orally administering to a patient in need thereof a lipase composition.

[0053] In certain embodiments, the present invention is directed to a method of treating abdominal pain, the method comprising orally administering to a patient in need thereof a lipase composition.

[0054] In certain embodiments, the present invention is directed to a method of treating flatulence, the method comprising orally administering to a patient in need thereof a lipase composition.

[0055] In certain embodiments, the present invention is directed to a method of reducing the number of daily bowel movements, the method comprising orally administering to a patient in need thereof a lipase composition.

[0056] A method for reducing stool weight comprising orally administering to a patient in need thereof a lipase composition.

[0057] In certain embodiments, the present invention is directed to a method of improving stool form, the method comprising orally administering to a patient in need thereof a lipase composition.

[0058] In certain embodiments, the present invention provides (a) a lipase; (b) a liquid nutritional formulation.

[0059] In certain embodiments, the present invention is directed to a process for preparing a composition comprising including a lipase in a liquid nutritional formulation.

[0060] In certain embodiments, the lipase and excipients are granulated and / or extruded. Granulation can be, for example, wet granulation or dry granulation. Dry granulation is the process of forming granules or granules from powdered or solid substances to produce a granular material. Typically, granulation involves the agglomeration of fine particles into larger granules, e.g., in the size range of 0.01-3.0 mm (D50). Agglomeration processes can include, for example, the use of a blend, application of pressure to compress the blend (roller or tablet / slug compression), shredding or grinding the solid materials into fine granules or pellets, and sieving. Wet granulation is very similar, but can include the incorporation of a solvent in the mixing process to produce the agglomerates, and a drying method to remove the solvent once the granules are formed.

[0061] In certain embodiments, the lipase and excipients are compressed.

[0062] In certain embodiments, the lipase and excipients are spray dried, granulated, and / or extruded.

[0063] In certain embodiments, the lipase and excipients are spray dried and compressed.

[0064] In certain embodiments, the lipase and excipients are granulated and / or extruded and compressed.

[0065] In certain embodiments, the lipase and excipients are spray dried, granulated, and / or extruded and compressed.

[0066] In certain embodiments, the non-porcine lipase is a triacylglycerol hydrolase.

[0067] In certain embodiments, the non-porcine lipase has a molecular weight of about 30 kDa to about 45 kDa.

[0068] In certain embodiments, the non-porcine lipase has a molecular weight of about 37 kDa.

[0069] In certain embodiments, the non-porcine lipase comprises from about 295 to about 310 amino acids.

[0070] In certain embodiments, the non-porcine lipase comprises about 301 amino acids.

[0071] In certain embodiments, the non-porcine lipase is produced from Yarrowia lipolytica.

[0072] In certain embodiments, the non-porcine lipase is encoded by the Lip2 gene.

[0073] In certain embodiments, the non-porcine lipase is an adole lipase.

[0074] In certain embodiments, the porcine lipase is pancrelipase.

[0075] In certain embodiments, the excipient is an oligosaccharide.

[0076] In certain embodiments, spray drying forms particles having a D50 of about 1 micron to about 200 microns, about 1 micron to about 50 microns, 50 microns to about 150 microns, about 60 microns to about 120 microns, about 65 microns to about 85 microns, or about 70 microns to about 82 microns.

[0077] In certain embodiments, the excipient comprises maltodextrin, xylan, mannan, fucoidan, galactomannan, chitosan, raffinose, stachyose, pectin, inulin, levan, graminan, and amylopectin, sucrose, lactulose, lactose, maltose, trehalose, cellobiose, nigerotriose, maltotriose, melezitose, maltotriulose, raffinose, kestose, or mixtures thereof.

[0078] In certain embodiments, the ratio of lipase to one or more excipients is about 1:5 to about 5:1, about 1:3 to about 3:1, about 1:2 to about 2:1, about 1:1, or about 1:2.

[0079] In certain embodiments, spray drying is carried out at a pH of about 3 to about 5, about 2 to about 7, or about 6.

[0080] In certain embodiments, spray drying is carried out at an inlet temperature above about 125°C, or from about 100°C to about 250°C, or from about 150°C to about 180°C, or from about 155°C to about 165°C, or about 162°C, and / or an outlet temperature below about 150°C, or from about 50°C to about 125°C, or from about 60°C to about 100°C.

[0081] In certain embodiments, spray drying produces lipase in a yield of greater than about 80%, greater than about 90%, greater than about 95%, or greater than about 99%.

[0082] In certain embodiments, the composition includes an enteric material.

[0083] In certain embodiments, the malabsorption is due to EPI and the insufficiency is caused by pancreatic resection, such as due to pancreatic cancer.

[0084] In certain embodiments, the deficiency is age-related or due to Shwachman-Diamond syndrome, type 1 diabetes, type 2 diabetes, HIV, celiac disease, or inflammatory bowel disease.

[0085] In certain embodiments, the deficiency results from ulcerative colitis or Crohn's disease.

[0086] In certain embodiments, at least a portion of the lipase is delivered to the duodenum of the patient.

[0087] Other embodiments In certain embodiments, the formulations utilized in the methods disclosed herein are delayed or immediate or sustained release oral dosage forms that include a lipase, such as a non-porcine lipase. In alternative embodiments, the dosage form includes an enteric material that includes or is dispersed with the lipase.

[0088] In certain embodiments, a spray-dried lipase disclosed herein is utilized in the method.

[0089] In certain embodiments, the formulations and methods disclosed herein include a second agent, which may be an additional lipase or active agent. The second agent may be selected from fat-soluble vitamins, proteases, amylases, porcine pancreatic enzyme supplements, other non-porcine supplements, or combinations thereof. In certain embodiments, the vitamins are A, D, E, K, or combinations thereof. In other embodiments, the second active agent is pancrelipase, liprotamase, or combinations thereof.

[0090] In certain embodiments, the lipase and the second active agent are each independently immediate release, delayed release, sustained release, or a combination thereof.

[0091] In certain embodiments, the dosage forms utilized herein are contained in a capsule, which optionally includes an enteric material, e.g., coated on or dispersed within the capsule, hi other embodiments, the enteric material is spray dried with the active agent, or the spray dried active agent is mixed with the enteric material.

[0092] In certain embodiments, the dosage form comprises adullipase in an amount of about 0.5 g per day to about 10 g per day, about 2 g per day to about 5 g per day, or about 2 g per day to about 4 g per day. In certain embodiments, the dosage is about 1.6 g per day, about 2.2 g per day, or about 4.4 g per day.

[0093] In certain embodiments, the dosage forms disclosed herein include tablets that optionally include an enteric material, for example, coated on or dispersed within the tablet.

[0094] In certain embodiments, the lipase (e.g., adullipase) may be in the form of a powder, optionally including an enteric coating material, for example, by dry blending, wet granulation, or co-spray drying or co-lyophilization.

[0095] In certain embodiments, the formulation is a powder or particles and is contained in a capsule, sachet, or powder paper.

[0096] In certain embodiments, the enteric material comprises a naturally occurring or non-naturally occurring material.

[0097] In certain embodiments, the enteric material comprises a cellulosic material, an acrylic polymer, or a combination thereof.

[0098] In certain embodiments, the enteric material comprises hydroxypropyl methylcellulose acetate succinate.

[0099] In certain embodiments, the enteric material comprises a methacrylic acid polymer, a cellulose acetate phthalate polymer, a hydroxypropyl methylcellulose acetate succinate polymer, a hydroxypropyl methylcellulose phthalate polymer, a polyvinyl acetate phthalate polymer, or a combination thereof.

[0100] In certain embodiments, the enteric material comprises methyl acrylate-methacrylic acid copolymer, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymer, shellac, or a combination thereof.

[0101] In certain embodiments, the enteric material is hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methylcellulose succinate, hydroxyethyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxyethyl methylcellulose acetate succinate, hydroxyethyl methylcellulose acetate phthalate, carboxyethyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate, methylcellulose acetate phthalate, ethyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate succinate, hydroxypropyl methylcellulose acetate succinate phthal ... cellulose acetate trimellitate, cellulose propionate phthalate, hydroxypropyl cellulose butyrate phthalate, cellulose acetate trimellitate, methyl cellulose acetate trimellitate, ethyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate, hydroxypropyl methyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate succinate, cellulose propionate trimellitate, cellulose butyrate trimellitate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate pyridine dicarboxylate, salicylic acid cellulose acetate, hydroxypropyl salicylic acid cellulose acetate, ethyl benzoic acid cellulose acetate, hydroxypropyl ethyl benzoic acid cellulose acetate, ethyl phthalic acid cellulose acetate, ethyl nicotinic acid cellulose acetate, ethyl picolinic acid cellulose acetate, or combinations thereof.

[0102] In certain embodiments, the enteric material is insoluble or substantially insoluble at a pH of less than about 4, less than about 3, or less than about 2.

[0103] In certain embodiments, the enteric material does not crack, break, or burst at a pH of less than about 4, less than about 3, or less than about 2.

[0104] In certain embodiments, the enteric material is soluble or substantially soluble at a pH greater than about 5, greater than about 5.5, greater than about 6, greater than about 7, or greater than about 8.

[0105] In certain embodiments, the enteric material does not crack, break, or burst at a pH greater than about 5, greater than about 5.5, greater than about 6, greater than about 7, or greater than about 8.

[0106] In certain embodiments, the dosage forms disclosed herein release less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase (e.g., adole lipase) in 30 minutes when tested in 900 mL of simulated gastric fluid at 37° C., at 100 rpm, with or without a sinker, in a USP Apparatus II (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2).

[0107] In certain embodiments, the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase (e.g., adole lipase) in 60 minutes when tested in 900 mL of simulated gastric fluid at 37° C., at 100 rpm, with or without a sinker, in a USP Apparatus II (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2).

[0108] In certain embodiments, the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase (e.g., adole lipase) in 90 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2) in a USP Apparatus II with or without a sinker at 100 rpm at 37°C.

[0109] In certain embodiments, the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase (e.g., adole lipase) in 120 minutes when tested in 900 mL of simulated gastric fluid at 37° C., at 100 rpm, with or without a sinker, in a USP Apparatus II (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2).

[0110] In certain embodiments, the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% of one or more of the active agents in 30 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2) in a USP Apparatus II with or without a sinker at 100 rpm at 37° C.

[0111] In certain embodiments, the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% of one or both of the active agents in 60 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2) at 37° C., at 100 rpm, with or without a sinker, in a USP Apparatus II.

[0112] In certain embodiments, the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% of one or both of the active agents in 90 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2) in a USP Apparatus II with or without a sinker at 100 rpm at 37° C.

[0113] In certain embodiments, the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% of one or both of the active agents in 120 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH below 3.0, e.g., 3.0 and / or 1.2) in a USP Apparatus II with or without a sinker at 100 rpm at 37° C.

[0114] In certain embodiments, the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase (e.g., adole lipase) in 15 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH 5.5 or greater, e.g., 5.5 or 6.0) in a USP Apparatus II with or without a sinker at 100 rpm at 37°C.

[0115] In certain embodiments, the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase (e.g., adole lipase) in 30 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH 5.5 or greater, e.g., 5.5 or 6.0) in a USP Apparatus II with or without a sinker at 100 rpm at 37° C.

[0116] In certain embodiments, the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase (e.g., adole lipase) in 45 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH 5.5 or greater, e.g., 5.5 or 6.0) in a USP Apparatus II with or without a sinker at 100 rpm at 37°C.

[0117] In certain embodiments, the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase (e.g., adole lipase) in 60 minutes when tested in 900 mL of simulated gastric fluid (at one or more points of buffer pH 5.5 or greater, e.g., 5.5 or 6.0) in a USP Apparatus II with or without a sinker at 100 rpm at 37° C.

[0118] In certain embodiments, the dosage forms disclosed herein target the release of lipase (eg, adullipase) in the duodenum of a patient in need thereof.

[0119] In certain embodiments, the lipase (eg, adlulipase) lipase is prepared by a process that includes drying, such as freeze drying or spray drying.

[0120] In certain embodiments, the spray drying utilizes a stabilizer such as an oligosaccharide, for example, maltodextrin.

[0121] In certain embodiments, the dried non-porcine lipase is in the form of a powder or particles. The particles can have a particle size having a D50 of, for example, about 1 micron to about 200 microns, about 1 micron to about 50 microns, 50 microns to about 150 microns, about 60 microns to about 120 microns, about 65 microns to about 85 microns, or about 70 microns to about 82 microns.

[0122] In certain embodiments, the stabilizer is maltodextrin, xylan, mannan, fucoidan, galactomannan, chitosan, raffinose, stachyose, pectin, inulin, levan, graminan, and amylopectin, sucrose, lactulose, lactose, maltose, trehalose, cellobiose, nigerotriose, maltotriose, melezitose, maltotriulose, raffinose, kestose, arginine, glycine, CaCl2, or mixtures thereof.

[0123] In certain embodiments, the ratio of active agent to stabilizer is about 1:5 to about 5:1, about 1:3 to about 3:1, about 1:2 to about 2:1, about 1:1, or about 1:2.

[0124] In certain embodiments, spray drying is carried out at a pH of about 3 to about 5, about 2 to about 7, about 4, or about 6.

[0125] In certain embodiments, spray drying is carried out at a temperature greater than about 125°C, greater than about 150°C, or from about 100°C to about 250°C, or from about 150°C to about 180°C, or from about 155°C to about 165°C.

[0126] In certain embodiments, spray drying produces a non-porcine lipase in a yield of greater than about 80%, greater than about 90%, greater than about 95%, or greater than about 99%.

[0127] In certain embodiments, the method of treatment is solely the non-porcine lipase formulations disclosed herein without the co-administration of a second active agent such as fat soluble vitamins (e.g., vitamins A, D, E, K, and combinations thereof), proteases, amylases, porcine pancreatic enzyme supplements, other non-porcine supplements, pancrelipase, liprotamase, a combination of the three enzymes: lipase, protease, and amylase, or combinations thereof.

[0128] In certain embodiments, the dosage form is administered through a feeding tube in the form of a solution or suspension, or in the form of a powder sprinkled on food, or administered as an oral dosage form such as a capsule, powder, tablet, liquid or semisolid.

[0129] In certain methods disclosed herein, at least a portion of the lipase (e.g., adullipase) is delivered to the duodenum of the patient, which portion can be, for example, at least about 75%, at least about 85%, or at least about 95%.

[0130] In certain embodiments, the formulations and methods provide a CFA% of about 80 to about 92, about 85 to about 92, about 86 to about 92, or about 90 to about 92 in an individual patient or subject.

[0131] In certain embodiments, the formulations and methods provide a CNA% of about 90 to about 99, about 92 to about 99, about 95 to about 99, or about 99 to about 99 in an individual patient or subject.

[0132] In certain embodiments, the formulations and methods provide a CNA% of about 90 to about 99, about 92 to about 99, about 95 to about 99, or about 99 to about 99 in a population of patients or subjects.

[0133] In certain embodiments, the formulations and methods provide an increase in CFA of about 3% to about 12%, about 4% to about 10%, about 2% to about 6%, about 3% to about 6%, about 4%, about 5%, or about 6% relative to the average.

[0134] In certain embodiments, the formulations and methods provide a maximum individual relative CFA increase of about 5% to about 50%, about 10% to about 45%, about 15% to about 40%, about 20% to about 50%, about 30% to about 40%, about 30%, about 35%, or about 40%.

[0135] In certain embodiments, the present invention is directed to preparing the compositions and formulations disclosed herein.

[0136] In certain embodiments, the non-porcine lipase is an acid-stable lipase (LIP2) secreted from the yeast Yarrowia lipolytica. It belongs to the family of triacylglycerol lipases. It shares the common fold of a / b hydrolases and its crystal structure has been solved.

[0137] LIP2 is a 301 amino acid protein that is secreted in the culture medium as a glycosylated mature form after cleavage of a 39 amino acid signal peptide. Alternative cleavage has been demonstrated on the lipase resulting in N-terminal sequence heterogeneity. The predominant N-terminal sequence was identified as STETSHIDQESYNFF in the spray-dried powder. This protein is also referred to as MS1819 or adole lipase.

[0138] Two N-glycosylation sites have been identified at residues N113 and N134, and analysis by mass spectrometry revealed that each site has the following sugar moiety GlcNAc2-Manx (x=8). Five major glycoforms have been demonstrated by isoelectric focusing gel (IEF). In certain embodiments, the drug substance is defined as a spray-dried active agent bulk solution after addition of maltodextrin in a ratio of 1:3 to 3:1 or 2:1 (based on bulk dry weight). In other embodiments, the drug substance is defined as an active agent prepared by spray drying maltodextrin in a ratio of 1:3 or 3:1 or 2:1 and an enteric polymer (e.g., HPMCAS) in a ratio of 1:10 to 10:1 or about 5:1. The active agent may also have 1 to 15% salt.

[0139] The sequence is as follows (SEQ ID NO:1): VYTSTETSHIDQESYNFFEKYARLANIGYCVGPGTKIFKPFNCGLQCAHFPNVELIEEFHDPRLIFDVSGYLAVDHASKQIYLVIRGTHSLEDVITDIRIMQAPLTNFDLAANISSTATCDDCLVHNGFIQSYNNTYNQIGPKLDSVIEQY PDYQIAVTGHSLGGAAALLFGINLKVNGHDPLVVTLGQPIVGNAGFANWVDKLFFGQENPDVSKVSKDRKLYRITHRGDIVPQVPFWDGYQHCSGEVFIDWPLIHPPLSNVVMCQGQSNKQCSAGNTLLQQVNVIGNHLQYFVTEGVCGI.

[0140] The following examples are provided to aid in the understanding of the present invention, and should not be construed as specifically limiting the present invention as described and claimed herein. Such variations of the present invention, including the substitution of all equivalents now known or later developed that would be within the skill of a person skilled in the art, and changes in formulations or minor changes in experimental design, should be construed as being included within the scope of the invention incorporated herein. Example 1A

[0141] The formulation of adullipase enteric coated capsules was prepared according to Table 1.A. [Table 1]

[0142] The preparation method followed the following process.

[0143] Step 1: Microcrystalline cellulose (MCC) is sieved through a rotary sieve with a screen of 1.0 mm mesh size and divided into two portions. Half of the microcrystalline cellulose is added to a 60 L drum. Adole lipase is sieved through a rotary sieve with a screen of 1.0 mm mesh size and introduced into the drum containing microcrystalline cellulose. The remaining microcrystalline cellulose is added to the drum containing microcrystalline cellulose and Adole lipase. Sodium starch glycolate is screened through a rotary sieve with a screen of 1.0 mm mesh size directly into a stainless steel drum containing microcrystalline cellulose and Adole lipase.

[0144] Step 2: Mix the three ingredients at 10 rpm for 10 minutes.

[0145] Step 3: The magnesium stearate is sieved through a rotary sieve having a 1.0 mm mesh size screen directly into the drum containing the preblend.

[0146] Step 4: Mix the blend for 6 minutes at 10 rpm.

[0147] Step 5: Using a fully instrumented rotary tablet press, the final blend is compressed with 19mm tooling.

[0148] Step 6: The tablets are then crushed using a rotary sieve having a grid screen with a mesh size of 1.5 mm.

[0149] Step 7: Magnesium stearate is weighed and sieved through a rotary sieve having a 1.0 mm mesh size screen and transferred to the stainless steel drum containing the blend.

[0150] Step 8: Blend the drums in a bin blender for 10 minutes at 10 rpm.

[0151] Step 9: The final blend is filled into hard capsules of theoretical mass 560 mg using fully instrumented encapsulation equipment. The hard capsules are enteric coated and contain hydroxypropyl methylcellulose.

[0152] Step 10: The capsules are sorted by a weighing machine with a mass tolerance of ±5% of the theoretical mass.

[0153] Example 1B Adole lipase powder was prepared by spray drying with (w / w%): 54.4% adole lipase: 27% maltodextrin: 10% HPMCAS: 8.4% salt. Other embodiments may have 40%-75% adole lipase, 10-40% maltodextrin, 5-20% HPMCAS, and 1-15% salt.

[0154] Granulation was prepared using Adole Lipase spray dried powder (69%), microcrystalline cellulose (30%, 10% x 3) and 1% magnesium stearate.

[0155] MCC was added in three portions, followed by geometric mixing for 5 minutes, the mixture was sieved through a 425 micron mesh, then compressed into 100 mg tablets at 1000 psi, followed by granulation through an 850 micron mesh to provide a powder with a D50 of 111 micrograms. Another portion was compressed into 200 mg tablets at 2000 psi, followed by granulation through an 850 micron mesh to provide a powder with a D50 of 455 microns.

[0156] Example 2 A clinical trial was conducted to evaluate the safety and efficacy of the adullipase enteric capsule of Example 1 in patients with cystic fibrosis. The study is a phase 2, open-label, multicenter, 2 × 2 crossover trial to evaluate the safety and efficacy of adlulipase (formerly MS1919) in an enteric-coated capsule in approximately 30 patients with EPI due to CF.

[0157] The primary objective of this study was to evaluate the safety and efficacy of porcine pancreatic enzyme replacement therapy (PERT) with adlulipase in an enteric-coated capsule in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).

[0158] There were two groups, and patients were randomized to participate in either the 2.2 g / day or 4.4 g / day adlulipase group. The duration of adlulipase treatment was 3 weeks.

[0159] The formulation was safe and well tolerated at all doses tested. Preliminary results for CFA% (n=24) were a mean CFA% of about 59, a minimum CFA% of 24, and a maximum CFA% of about 92%, with the number of patients above 80% being 5, and preliminary results for CNA% (n=24) were a mean CNA% of about 93, a minimum CAN% of 83, and a maximum CAN% of 99, with the number of patients above 90 being 22. The data showed a lack of a dose-response relationship.

[0160] The coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA) of PERT are typically around 86 and 97, respectively.

[0161] As shown in Example 2, the CFA of the present formulation approached and exceeded this value in certain individual subjects.

[0162] As further demonstrated in Example 2, the mean CNA of the subject population was about 93. This is surprising because it demonstrates that lipase alone is sufficient to treat EPI without the need for supplemental protease (although the two agents may still be combined).

[0163] Example 3 The dissolution experimental setup used is USP <711> It is similar to the dissolution apparatus 2 (paddle) described in, but miniaturized.

[0164] The buffers used were sodium acetate 20 mM for the pH range of 2.0-4.0 and MES 20 mM for the pH range of 5.0-6.0.

[0165] A jacketed vessel conditioned at 37°C was filled with 150 ml of buffer (pH 2-6) with or without pepsin (0.1 mg / ml). Stirring was performed using a magnetic stirrer set at a moderately low stirring speed (level 2). At t=0, the capsule was weighed and then placed into the holder / sinker.

[0166] At time points 15, 30, 45 and 60 min 20 μl samples were taken for assay. At t=60′ the pH was switched to 6 by adding NaOH 1N.

[0167] At 105 min (45 min after buffer exchange), 20 μl was taken for assay.

[0168] For analysis, 20 μl of lysis medium was mixed with 5 μl of 5x loading buffer.

[0169] Three standard lipase DS samples of 2, 5, and 10 μg, respectively, were prepared by mixing 2, 5, and 10 μl of a 1 mg / mL C159001 solution in phosphate buffer (50 mM Na2HPO4 pH=6.0) with 5 μl of 5x loading buffer, and elution buffer was added to obtain a final volume of 25 μl.

[0170] Samples (25 μl) were run using TGX stain-free AnyKDa Miniprotean 10 well, 50 μl / well for 18 min at 300 V. Imaging was performed on the stain-free plate with BIORAD's GelDoc EZ according to BIORAD's manufacturer's instructions.

[0171] For dissolution of technical batch 20P002, simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared as adapted from the Minekus et al. paper. 100 ml stocks of the following buffers were prepared and combined as shown in Table 3.A below: [Table 2]

[0172] As demonstrated, immediate release formulation is not protected at low pH. In contrast, enteric capsule formulation is protected at low pH and does not dissolve at pH, for example, below 5.5. Therefore, enteric capsule formulation can deliver a larger amount of enzyme to duodenum to digest fat.

[0173] Example 4 A clinical combination test was conducted using the following protocol, and the results are shown in Figure 2.

[0174] The study is a multicenter, open-label, phase 2 trial using escalating doses of adolelipase-SD (spray-dried adolelipase in immediate-release capsules) in addition to a stable dose of PPE to investigate the efficacy and safety of this combination for compensation of severe exocrine pancreatic insufficiency in CF patients who are not fully compensated with PPE alone.

[0175] The primary efficacy objective is to determine the efficacy of increasing doses of adenolipase-SD in addition to a stable dose of porcine pancreatic extract (PPE) on triglyceride digestion as assessed by coefficient of fat absorption (CFA) in patients with severe exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF) and not fully compensated with PPE alone.

[0176] The primary safety objective is to evaluate the safety and tolerability of escalating doses of adlulipase-SD in addition to a stable dose of PPE in patients with severe EPI caused by CF.

[0177] The design was a multicenter, open-label, interventional study conducted in male and female patients with severe EPI caused by CF to investigate the safety and efficacy of increasing doses of adullipase-SD in addition to stable doses of PPE. The study will be conducted in four separate phases: Phase A: Screening • All potential patients will be informed of the study's objectives and procedures. • Patients must be willing to provide written informed consent to participate in the study. • Patients affected by CF will be checked for all eligibility criteria. Only patients who have been treated with a stable dose of PPE for ≥ 1 month may participate in the study. A stable dose is defined as a dose of drug that has not been changed during this period, and the drug must be marketed and administered within the recommended dose range. ●Perform a complete physical examination. ●Check medical history. ●Specific evaluation for CF (including pulmonary function testing with spirometry assessment to determine a forced vital capacity in 1 second [FEV1] ≥ 30% of predicted normal for age, sex, and height at screening, and sweat chloride testing). Measurement of fecal human pancreatic elastase-1 (FE-1) concentration within the last month is required. If not available, a stool sample for measurement of FE-1 concentration will be provided at the screening visit. Only patients with fecal human pancreatic elastase-1 concentration <100 μg / g stool will be suggested to proceed to Phase B.

[0178] Phase B: Baseline with Coefficient of Fat Absorption (CFA) measurements under routine stable doses of Porcine Pancreatic Extract (PPE) and inclusion • Following appearance of fecal dye markers, the patient's CFA will be measured in the inpatient facility on a standardized high-fat diet for 72 hours and under standard doses of PPE. A first dye marker will be given to participants with the first high-fat diet and a second dye marker will be given at the end of the 72-hour high-fat diet period. The first stool containing the dye is discarded. The stool is then collected, containing the first stool marked with the second dye marker. ●Calculation of CFA is based on fecal fat content measured in relation to the amount of fat ingested during a 72-h period. The amount of fat ingested per day is corrected to the actual amount by subtracting the amount of residual food per meal / snack using dietary assessment. A mean fat intake over a 72-h stool collection period of less than or greater than the planned amount of 85-115 g per 24 h invalidates the CFA assay for per-protocol analysis. According to US and European guidelines, only patients with a CFA <80% at a maximum daily dose of 10,000 lipase units / kg / day will proceed to Phase C. • A minimum protein intake of 1.5-2 g / kg / day should be provided in the diet planned by a nutritionist for the purpose of assessing CNA.

[0179] Phase C: Open-label escalating doses of adullipase-SD (Cycles 1 to 3) Routine PPE (e.g., Creon® (pancrelipase) or Zempep® (pancrelipase)) will be continued throughout Phase C. Patients will receive increasing doses of Adrenolipase-SD using the following three dose regimens for 15 days (± 2 days) of each dose regimen: 700 mg / day, 1120 mg / day, and 2240 mg / day. The dosage is divided as follows: -700mg / day: One 140mg capsule with each of three main meals and two snacks -1120 mg / day: Two 140 mg capsules with each of three main meals and one capsule with each of two snacks -2240 mg / day: Four 140 mg capsules with each of three main meals and two capsules with each of two snacks ● Each dose of Adolelipase-SD will be administered for the entire planned 15-day period (± 2 days) of the dosing regimen from the start of each dose escalation until the next clinic visit. • CFA and CNA will be measured for 72 hours under adullipase-SD treatment, in an inpatient facility, and on a standardized high-fat diet. ● Escalation to the next dose regimen in each subject will be permitted after a thorough review of the safety and tolerability of the preceding dose. -The total duration of treatment with Adolelipase-SD (any dose) is up to 51 days.

[0180] Phase D: Follow-up / Early Termination Standard PPE treatment will continue after completion of Adollipase-SD intake. Follow-up visits will be scheduled 12-15 days after completion of Phase C.

[0181] Patients will receive increasing doses of Adolelipase-SD according to the following titration ranges: 700 mg / day, 1120 mg / day, and 2240 mg / day.

[0182] Adolelipase-SD is supplied as capsules of 140 mg each to be administered orally and taken with food.

[0183] The estimated study duration is approximately 90 days (including up to 15 days for phase A (screening period), 15 days for phase B (routine stable dose PPE and CFA measurements under inclusion), followed by a treatment period of 15 ± 2 days for each cycle 1 to 3 of phase C (open-label escalating dose of adlulipase-SD), and 12 to 15 days for phase D (follow-up)).

[0184] To be eligible to participate in the study, patients must meet all of the following criteria: 1. A signed and dated informed consent form. 2. Age 12 years at screening 3.Male or female. 4. Under stable dose of PPE for ≥ 1 month. Stable dose is defined as the dose of drug that does not change during this period and the drug must be marketed and administered within the recommended dose range. 5. Nutritional status defined by: a. For female patients, BMI ≤ 22.0 kg / m2 b. For male patients, BMI ≤ 23.0 kg / m2 c. BMI ≤ 50th percentile for patients aged 12 to < 18 years. 6. Cystic fibrosis (CF) based on at least two clinical features consistent with CF in the investigator's opinion and sweat chloride concentration >60 mmol / L by pilocarpine iontophoresis. 7. Fecal pancreatic elastase-1 at screening, <100 μg / g stool. 8. Baseline CFA <80% with a maximum daily dose of 10,000 lipase units / kg / day. 9. Clinically stable with no documented evidence of significant respiratory symptoms requiring intravenous antibiotics, supplemental oxygen, or hospitalization within 30 days of screening. 10. Male and female patients must use a reliable method of birth control during the study if they are of childbearing potential. A reliable method of birth control is defined as one of the following: oral or injectable contraceptives, intrauterine devices, contraceptive implants, tubal ligation, hysterectomy, or double-failure contraception (diaphragm with spermicidal foam or jelly, or condoms), abstinence, or vasectomy. Periodic abstinence (calendar, symptom-fever, or postovulation methods) is not an acceptable method of birth control. The patient's preferred usual lifestyle must also be evaluated when determining whether sexual abstinence is a reliable method of birth control. 11. Be deemed reliable and competent to comply with the protocol according to the Investigator's judgment.

[0185] The exclusion criteria were as follows: 1. Established or suspected colonic fibrosis. 2. Total or partial gastrectomy. 3. History of solid organ transplant or major surgical resection of the intestine; major resection of the intestine is defined as any resection of the terminal ileum or ileocecal valve. Patients who have had a qualitative, long-term change in nutritional status after other intestinal resection (e.g., a new increased need for pancreatic enzyme supplementation compared to preoperative status to maintain the same nutritional status) should also be excluded. 4. Any chronic diarrheal disease unrelated to pancreatic insufficiency (e.g., infectious gastroenteritis, sprue, inflammatory bowel disease) 5. Known hypersensitivity or other severe reaction to any component of the investigational medicinal product (IMP). 6. Bilirubin, >1.5x upper limit of normal (ULN). 7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST), >5x ULN. 8. Alkaline phosphatase (ALP), >5x ULN. 9. Gamma glutamyltransferase (GGT), >5x ULN. 10. Signs and / or symptoms of cirrhosis or portal hypertension (e.g., splenomegaly, ascites, esophageal varices) or documented liver disease unrelated to CF 11. Known allergy to stool markers. 12. Nutritional intake via enteral tube in the 6 months prior to screening 13. Daily use of antidiarrheal, antispasmodic, or antidiarrheal laxatives within the last 12 months prior to screening, or a change in chronic osmotic laxative (e.g., polyethylene glycol) regimen in previous laxative therapy within the last 12 months prior to screening 14. History of severe constipation with <1 bowel movement / week under adequate laxative therapy within the last 12 months prior to screening. 15. Documented distal intestinal pseudo-obstruction syndrome within the last 12 months prior to screening. 16. Forced vital capacity ≤ 30% at the screening visit. 17. Lactating or known pregnant or of childbearing potential in a woman or women with a positive pregnancy test at both screening and baseline. 18. Participation in another clinical trial involving IMP within 30 days prior to or concomitant with this study. 19. Poorly controlled diabetes mellitus as judged by the investigator.

[0186] Standard of care medications for CF, including antibiotics, mucolytics, aerosols, and CFTR modifiers, are permitted. CFTR modulators must be on a stable dose for at least 3 months. Patients must not start taking CFTR modulators during the study period. Gastric acid suppressants are permitted but must be stable for 30 days prior to screening and the dosage may not be changed or stopped during the study.

[0187] The prohibited drugs are: Orlistat lipase inhibitors (e.g., AlliR®, Xenical®), Laxatives consisting of mineral oil and castor oil (chronic use of osmotic laxatives is permitted) ● Symptomatic treatment of diarrhea: loperamide (generic loperamide, Imodium®, Imodium AD®, Diamode®, Imotil®, Kao-Paverin®), atropine / diphenoxylate (Lonox®), atropine / diphenoxylate (Lomocot®).

[0188] The primary efficacy endpoints were: • Change in CFA from baseline (V2) to visits in Phase C (V4, V5, and V6).

[0189] Secondary endpoints are as follows: Key secondary endpoints: • Change from phase B in the mean number of daily bowel movements during the stool collection period in the phase C cycle. • The mean change from Phase B in stool form as assessed by the Bristol scale during the stool collection period in each complete cycle of Phase C. Other secondary endpoints: ●Weight. ●Body mass index. • Faeces weight during stool collection period (every 24 hour and over 72 hour collection period). • Abdominal discomfort assessed by visual analogue scale. • Absorption variables: CNA and steatorrhea. • Change from Phase B in the mean number of daily excretions per day across each complete cycle in Phase C. • The mean change from Phase B in stool form as assessed by the Bristol Scale across each complete cycle of Phase C.

[0190] Safety data including all observed adverse events with special focus on immunological / allergic events and gastrointestinal symptoms.

[0191] Secondary safety endpoints are as follows: In addition to the primary safety endpoints, clinical laboratory results will be summarized. ●Fasting glucose. Urine tests • Hematology: Hematocrit, hemoglobin, red blood cell count (RBC), white blood cell count (WBC), absolute counts of: neutrophils (segmented), immature neutrophils (bands), lymphocytes, monocytes, eosinophils, basophils, and platelets. • Biochemistry: Serum concentrations of: sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), total calcium, phosphorus, magnesium, albumin, prealbumin, total protein, creatinine, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), total bilirubin, direct bilirubin, and uric acid. Fasting lipid profile: total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL) • Serum vitamins A, D, E, and K. ● Activated partial thromboplastin time (aPTT), prothrombin time / international normalized ratio (PT / INR) • Immunogenicity assessment of circulating levels of LIP2 lipase. ●Antibody against LIP2.

[0192] Sample size determination will be based on the primary efficacy endpoint, baseline change in CFA from Phase C baseline (V2) to Visits V4, V5, and V6.

[0193] Assuming a standard deviation of change in CFA of 15%, an expected mean CFA change of 10% for at least one dose of adullipase-SD (700 mg / day, 1120 mg / day, or 2240 mg / day), and a two-sided nominal alpha level of 0.05, 20 patients will be sufficient to achieve a power of 80%. To account for possible dropouts during dose escalation, 24 patients will be enrolled.

[0194] Twenty-four patients are considered sufficient to adequately evaluate the safety of each studied dose. Because there is some uncertainty about the expected standard deviation of change in CFA in the studied population, the standard deviation will be re-estimated at an interim stage (after 15 patients have completed phase C). If the estimated standard deviation is larger than planned, the sample size will be increased to maintain power.

[0195] Efficacy Analysis Set Full Analysis Set (FAS): defined as all patients who received at least one dose of treatment and had some efficacy assessment available on treatment. The FAS is considered the primary set for efficacy analyses. • Per Protocol Set (PP): A subset of the FAS that includes all patients who have not violated the terms of the protocol in a way that would significantly affect the outcome of the trial, as determined by the trial clinician.

[0196] Safety Set: ●The safety set will be defined as all patients who received at least one dose of adullipase-SD. • Patients are analysed according to the treatment they actually received.

[0197] Efficacy Analysis: Primary efficacy endpoint: The primary analysis will be performed on the FAS. The primary efficacy endpoint (change in CFA during Phase C) will be analyzed with a mixed model for repeated measures (MMRM) including a random term for patient, a fixed term for visit, and baseline CFA as a covariate. Estimation will be performed using a restricted maximum likelihood (REML) approach under the assumption of an unstructured covariance matrix for repeated measures. The mean change in CFA from baseline to each escalated dose visit will be estimated along with its 95% confidence interval and p-value, assuming that baseline CFA was set to its mean level estimated at baseline.

[0198] Sensitivity analysis of primary efficacy endpoint The primary efficacy outcome will be analyzed at each visit using an analysis of covariance (ANCOVA) model with intercept and baseline CFA. Missing data will not be imputed. • This ANCOVA analysis was also performed with missing data replaced by the Last Observation Carried Forward (LOCF) method.

[0199] Dose-response modeling A random coefficient model is fitted to assess the dose-response relationship. The dose taken during each titration period is included as a linear and quadratic (dose squared) fixed covariance matrix. The model also includes random terms for the dose intercept, linear and quadratic trends assuming unstructured covariance matrices for these parameters. If convergence problems occur when fitting the model, the linear trend is only maintained in the model.

[0200] Subgroup analysis Analyses are performed in the following subgroups: Age (<18 vs. ≥18) Use of PPIs (yes vs. no)

[0201] Key secondary efficacy endpoints: Change from baseline in the mean number of daily bowel movements during the stool collection period during each escalating dose in Phase C Change from baseline in mean stool form as assessed by the Bristol Scale during the stool collection period during each escalating dose in Phase C

[0202] Other secondary endpoint analyses: Analyses of other secondary efficacy endpoints are detailed in the statistical analysis plan.

[0203] Safety Analysis: • Tabulate exposure to study drug and reasons for discontinuation or withdrawal. ●Safety will be assessed by the incidence, severity and type of adverse events, as well as changes from baseline (Phase B) in vital signs, weight, and clinical laboratory results in patients using the safety population.

[0204] The formulation was safe and well tolerated at all doses tested. Preliminary results (n=18) indicate a mean increase over baseline of approximately 5.9%, with a maximum increase over baseline of 34, a minimum increase over baseline of 16, and a number above 80% of 7. Data showed a lack of a dose-response relationship.

[0205] Target deployment: Of the 21 enrolled subjects, a total of 95.2% (20 / 21) subjects completed the study. One subject (4.8%) discontinued the study due to COVID-19 restrictions.

[0206] Demographics and baseline characteristics: Male subjects comprised 66.7% (14 / 21) of the safety population, and 33.3% (7 / 21) were female. Median age was 17.0 years (range: 12-32 years), and all subjects (100%, 21 / 21) were white. Median baseline BMI was 18.4 kg / m2 (range: 15, 22). Median time from cystic fibrosis diagnosis was 15.1 years (range: 9-33).

[0207] Efficacy Results: For the primary endpoint, CFA increased significantly in both the FAS and PP populations, with the highest increase being 5.99 from baseline to visit 4 in the PP population (p-value=0.0316).

[0208] Secondary outcomes included a significant reduction in the mean number of daily bowel movements in both the FAS and PP populations, with the highest reduction being 0.60 from baseline to visit 6 in the FAS population (p-value < 0.0001).

[0209] Regarding secondary outcomes, mean stool form increased significantly in both the FAS and PP populations. The highest decrease in the Bristol Scale was 0.70 from baseline to visit 6 in the PP population (p=0.004).

[0210] Other secondary outcomes (weight, BMI, stool weight, nitrogen excretion and steatorrhea) showed improvements.

[0211] Abdominal discomfort did not appear to alter clinical relevance.

[0212] These parameters were not tested for formal statistical significance.

[0213] Safety Results: Exposure to adullipase SD was approximately 2 weeks in all three treatment groups.

[0214] The number of subjects reporting any TEAE was 3 (14.3%) in the 700 mg / day period, 5 (23.8%) in the 1120 mg / day period, 4 (20.0%) in the 2240 mg / day period, and 1 (5%) in the follow-up period. Only 1 subject (4.8%) had one relevant TEAE in the 700 mg / day period.

[0215] No patients had TEAEs leading to permanent drug discontinuation, dose interruption, or dose reduction.

[0216] No patients had fatal, severe, or serious TEAEs.

[0217] A total of 2 patients (9.5%) each had one TEAE of special interest, with 1 patient (4.8%) having (PT: nausea) during the 1120 mg / day period and 1 patient (5%) having (PT: diarrhea) during the 2240 mg / day period.

[0218] Comparison of mean laboratory values ​​from baseline to subsequent visits for all clinical chemistry, hematology, and coagulation analytes did not demonstrate any clinically significant effect of Adolelipase SD on any parameter.

[0219] Mean vital sign results (diastolic and systolic blood pressure, heart and respiratory rates, and temperature) at visits after the first visit were similar to those at baseline.

[0220] Some immunogenicity was detected, including at baseline, suggesting pre-existing reactivity. No clinical signs or symptoms of immune reaction occurred during the study.

[0221] Changes in cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, vitamin A, 25-hydroxyvitamin D, vitamin E, vitamin K1, and glucose were consistent with improvement in malabsorption, although no tests of statistical significance were performed for these parameters.

[0222] conclusion A stable dose of PPE plus increasing doses of adullipase-SD (700 mg / day to 2240 mg / day) significantly increased CFA, decreased the number of daily bowel movements, and improved stool form. Body weight, BMI, stool weight, nitrogen excretion, and steatorrhea also showed improvements, although formal statistical significance was not tested for these parameters.

[0223] Adrenolipase-SD was safe and well tolerated at doses up to 2240 mg / day.

[0224] A summary of Example 4 is given below: Background: Adolelipase alfa (formerly MS1819) is a recombinant yeast-derived lipase for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), chronic pancreatitis (CP), and other indications. CF patients with EPI are currently prescribed porcine pancreatic enzymes (PPE) to promote food digestion and adequate nutrition. However, up to 25% of patients receiving PPE are not adequately controlled and present with refractory steatorrhea, symptoms of malabsorption, and weight loss. The reason for this may be reaching the maximum recommended dose of PPE or, in some cases, lack of tolerance to increased PPE doses. To evaluate the effect of adding Adolelipase to the enzyme regimen of CF patients, we conducted a clinical trial in several clinical centers in Hungary and Turkey. The primary objective of the clinical trial was to determine the safety and efficacy of Adolelipase in addition to a stable dose of PPE on triglyceride digestion as assessed by the coefficient of fat absorption (CFA).

[0225] Methods: See Figure 1 for study schematic. Male or female subjects ≥12 years of age at screening with a clinical diagnosis of CF under a stable dose of PPE for ≥1 month were enrolled. Subjects had to have nutritional status defined by a body mass index (BMI) of ≤22.0 kg / m2 for females, ≤23.0 kg / m2 for males, or ≤50th percentile for ages 12-<18. Subjects had to have fecal elastase <100 μg / g stool, baseline CFA <80%, and a maximum daily PPE dose of 10,000 lipase units / kg / day. CFA measurements were determined following a quantitative fecal fat test administered to patients on a 72-hour standardized high-fat diet.

[0226] Results: In the full analysis set (N=20), the mean CFA% at baseline was 67.3, and the mean increases in CFA% at Visits 4, 5, and 6 were 5.7, 6.6, and 5.0, respectively. The mean improvement in CFA compared to baseline was 5.7%. These results were supported by secondary endpoints including improvements in stool weight, stool form, stools per day, weight, and BMI (Table 1). A mean increase in weight of 1.7 kg (approximately 4 lbs) over 45 days was observed with the addition of adullipase.

[0227] Conclusions: Increasing doses of adole lipase (700 mg / day to 2240 mg / day) in addition to a stable dose of PPE resulted in a clinically significant increase in mean CFA in addition to improvements in signs, symptoms, and nutritional status (Brady et al, 2006). Adole lipase was safe and well tolerated when administered at increasing doses up to 2240 mg / day. The results of this study support further study of this product in patients currently not adequately controlled with PPE alone. We are currently developing an improved formulation of adole lipase with better protection from gastric acid, and potentially more lipase activity in the duodenum.

[0228] For ease of explanation, embodiments of the methods of the present disclosure are depicted and described as a series of operations. However, operations in accordance with the present disclosure may occur in various orders and / or simultaneously, as well as with other operations not shown and described herein. Moreover, not all illustrated operations may be required to implement a methodology in accordance with the disclosed subject matter. In addition, those skilled in the art will understand and appreciate that a methodology may alternatively be represented as a series of interrelated states via a state diagram or events.

[0229] In the above description, many specific details are set forth, such as specific materials, dimensions, process parameters, etc., to provide a thorough understanding of the invention. Particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments. The word "example" or "exemplary" is used herein to mean serving as an example, instance, or illustration. Any aspect or design described herein as "example" or "exemplary" should not necessarily be construed as preferred or advantageous over other aspects or designs. Rather, use of the word "example" or "exemplary" is intended to present concepts in a concrete manner. As used in this application, "or" is intended to mean an inclusive "or" rather than an exclusive "or." That is, unless otherwise specified or clear from the context, "X includes A or B" is intended to mean all natural inclusive permutations. That is, if X includes A, if X includes B, or if X includes both A and B, then "X includes A or B" is satisfied under any of the above illustrative examples. Furthermore, the articles "a" and "an" used in this application and the appended claims should generally be construed to mean "one or more" unless otherwise specified or clear from the context directed to the singular. References throughout this specification to "an embodiment," "certain embodiment," or "one embodiment" mean that the particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, the appearances of the phrases "one embodiment," "certain embodiment," or "one embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment.

[0230] References to numerical ranges throughout this specification should not be construed as limiting, but should be understood to include the outer limits of the ranges as well as each numerical and / or narrower range within the recited numerical ranges.

[0231] The invention has been described with reference to specific exemplary embodiments thereof. The specification and drawings are accordingly to be regarded in an illustrative rather than a restrictive sense. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.

Claims

1. 1. A method for treating a nutritional deficiency comprising orally administering to a patient in need thereof a lipase composition.

2. 10. The method of claim 1, wherein the lipase aids in the absorption of one or more of fat, vitamin A, vitamin D, vitamin E, and vitamin K.

3. 3. The method of claim 1 or 2, wherein the patient has improvement in one or more of weight gain, fatty stools, abdominal pain, bloating, daily bowel movement frequency, stool weight, and stool shape.

4. 4. The method of claim 3, wherein the patient experiences a 2% weight gain in a period selected from 3 months, 6 months, 9 months, or 12 months.

5. 4. The method of claim 3, wherein the patient experiences a 5% weight gain in a period selected from 3 months, 6 months, 9 months, or 12 months.

6. 4. The method of claim 3, wherein the patient experiences an 8% weight gain in a period selected from 3 months, 6 months, 9 months, or 12 months.

7. 4. The method of claim 3, wherein the patient experiences a 10% weight gain in a period selected from 3 months, 6 months, 9 months, or 12 months.

8. 4. The method of claim 3, wherein the patient experiences a 12% weight gain in a period selected from 3 months, 6 months, 9 months, or 12 months.

9. 13. The method of any of the preceding claims, wherein the lipase composition is administered once a day, twice a day, three times a day, or four times a day.

10. 13. The method of any of the preceding claims, wherein the lipase composition is administered with one or more meals.

11. 2. The method of any of the preceding claims, wherein the lipase composition is administered for at least 1 day, at least 7 days, at least 1 month, at least 3 months, at least 6 months, at least 9 months, or at least 12 months.

12. 13. The method of any of the preceding claims, wherein the lipase composition is administered together with a liquid nutritional formulation, such as a high-calorie nutritional supplement.

13. 13. The method of claim 12, wherein the lipase composition is administered simultaneously or sequentially with the liquid nutritional formulation.

14. 14. The method of claim 12 or 13, wherein the liquid nutritional formula is administered by a feeding tube.

15. The method according to any one of claims 12 to 14, wherein the lipase composition and the liquid nutritional formulation are part of the same composition.

16. 10. The method of any preceding claim, wherein the patient has EPI.

17. The method of any of claims 1 to 15, wherein the patient does not have EPI.

18. 10. The method of any preceding claim, wherein the patient is over 60 years of age.

19. 10. The method of any preceding claim, wherein the patient has cancer or acute pancreatitis.

20. 10. The method of any preceding claim, wherein the lipase composition comprises porcine lipase.

21. 13. The method of any preceding claim, wherein the lipase composition comprises a non-porcine lipase.

22. 2. The method of any of the preceding claims, wherein the lipase composition comprises adorlipase, pancrelipase, liprotamase, or a combination thereof.

23. The method of any one of claims 1 to 19, wherein the lipase composition comprises an adole lipase.

24. 2. The method of any preceding claim, wherein the lipase composition comprises an enteric material.

25. 22. The method of claim 21 , wherein the non-porcine lipase is a triacylglycerol hydrolase.

26. 22. The method of claim 21, wherein the non-porcine lipase has a molecular weight of about 30 kDa to about 45 kDa.

27. 27. The method of claim 26, wherein the non-porcine lipase has a molecular weight of about 37 kDa.

28. 22. The method of claim 21, wherein the non-porcine lipase comprises from about 295 to about 310 amino acids.

29. 29. The method of claim 28, wherein the non-porcine lipase comprises about 301 amino acids.

30. 22. The method of claim 21 , wherein the non-porcine lipase is produced from Yarrowia lipolytica.

31. 22. The method of claim 21 , wherein the non-porcine lipase is encoded by the Lip2 gene.

32. 22. The method of claim 21 , wherein the non-porcine lipase is an adole lipase.

33. 13. A method according to any preceding claim, comprising a capsule containing the lipase, the capsule comprising an enteric material, for example as a coating or dispersed within the capsule.

34. 33. The method of any of claims 1 to 32, comprising a tablet comprising the lipase, the tablet being overcoated with the enteric material or the enteric material being dispersed therein.

35. 13. The method of any preceding claim, wherein the lipase is combined with an enteric material in a solution and freeze-dried or spray-dried to form a powder.

36. The method of claim 1 , wherein the lipase is in solution or suspension in a medium.

37. 36. The method of claim 35, wherein the powder is contained in a capsule, sachet, or powder paper.

38. The method of any of claims 33 to 35, wherein the enteric material comprises a naturally occurring or non-naturally occurring material.

39. 39. The method of claim 38, wherein the enteric material comprises a cellulosic material, an acrylic polymer, or a combination thereof.

40. 39. The method of claim 38, wherein the enteric material comprises hydroxypropyl methylcellulose acetate succinate.

41. 39. The method of claim 38, wherein the enteric material comprises a methacrylic acid polymer, a cellulose acetate phthalate polymer, a hydroxypropyl methylcellulose acetate succinate polymer, a hydroxypropyl methylcellulose phthalate polymer, a polyvinyl acetate phthalate polymer, or a combination thereof.

42. 39. The method of claim 38, wherein the enteric material comprises methyl acrylate-methacrylic acid copolymer, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymer, shellac, or a combination thereof.

43. The enteric material is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methylcellulose succinate, hydroxyethyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxyethyl methylcellulose acetate succinate, hydroxyethyl methylcellulose acetate phthalate, carboxyethyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate, methylcellulose acetate phthalate, ethyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate succinate, hydroxypropyl methylcellulose acetate succinate phthalate, hydroxypropyl methylcellulose acetate succinate phthalate, hydroxypropyl methylcellulose succinate phthalate, cellulose protease, 40. The method of claim 38, comprising cellulose acetate trimellitate, hydroxypropyl cellulose butyrate phthalate, cellulose acetate trimellitate, methyl cellulose acetate trimellitate, ethyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate, hydroxypropyl methyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate succinate, cellulose propionate trimellitate, cellulose butyrate trimellitate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate pyridine dicarboxylate, salicylic acid cellulose acetate, hydroxypropyl salicylic acid cellulose acetate, ethyl benzoic acid cellulose acetate, hydroxypropyl ethyl benzoic acid cellulose acetate, ethyl phthalic acid cellulose acetate, ethyl nicotinic acid cellulose acetate, ethyl picolinic acid cellulose acetate, or combinations thereof.

44. 39. The method of claim 38, wherein the enteric material is insoluble or substantially insoluble at a pH of less than about 4.

45. 34. The method of claim 33, wherein the enteric material does not crack, break, or burst at a pH of less than about 4.

46. 39. The method of claim 38, wherein the enteric material is soluble or substantially soluble at a pH of greater than about 5.

47. 34. The method of claim 33, wherein the enteric material cracks, breaks or bursts at a pH above about 5.

48. 48. The method of any of claims 1-47, wherein the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase in 30 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of 3.0 or less).

49. 48. The method of any of claims 1-47, wherein the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase in 60 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of 3.0 or less).

50. 48. The method of any of claims 1-47, wherein the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase in 90 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of 3.0 or less).

51. 48. The method of any of claims 1-47, wherein the dosage form releases less than about 10%, less than about 5%, less than about 3%, or less than about 1% lipase in 120 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of ≦3.0).

52. 48. The method of any of claims 1-47, wherein the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase in 15 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of 5.5 or greater).

53. 48. The method of any of claims 1-47, wherein the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase in 30 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of 5.5 or greater).

54. 48. The method of any of claims 1-47, wherein the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase in 45 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of 5.5 pH or greater).

55. 48. The method of any of claims 1-47, wherein the dosage form releases at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the lipase in 60 minutes when tested in USP Apparatus II with a sinker at 100 rpm at 37°C in 900 mL of simulated gastric fluid (buffer pH of 5.5 or greater).

56. 56. The method of any of claims 1 to 55, wherein the lipase is targeted in the duodenum of a patient in need of its release.

57. 56. The method of any one of claims 1 to 55, wherein the lipase is prepared by lyophilization.

58. 56. The method of any one of claims 1 to 55, wherein the lipase is prepared by spray drying.

59. 59. The method of claim 58, wherein the spray drying utilizes a stabilizer.

60. 60. The method of claim 59, wherein the stabilizer is an oligosaccharide.

61. 61. The method of any of claims 57-60, wherein the drying forms particles having a D50 of about 1 micron to about 200 microns, about 1 micron to about 50 microns, about 50 microns to about 150 microns, about 60 microns to about 120 microns, about 65 microns to about 85 microns, or about 70 microns to about 82 microns.

62. 60. The method of claim 59, wherein the stabilizer is maltodextrin, xylan, mannan, fucoidan, galactomannan, chitosan, raffinose, stachyose, pectin, inulin, levan, graminan, and amylopectin, sucrose, lactulose, lactose, maltose, trehalose, cellobiose, nigerotriose, maltotriose, melezitose, maltotriulose, raffinose, kestose, or mixtures thereof.

63. 60. The method of claim 59, wherein the ratio of active agent to stabilizer is from about 1:5 to about 5:1, from about 1:3 to about 3:1, from about 1:2 to about 2:1, about 1:1 or about 1:

2.

64. 59. The method of claim 58, wherein the spray drying is carried out at a pH of about 3 to about 5, about 2 to about 7, or about 6.

65. 59. The method of claim 58, wherein the spray drying is carried out at a pH of about 4.

66. 59. The method of claim 58, wherein the spray drying is carried out at an inlet temperature of above about 125°C, or from about 100°C to about 250°C, or from about 150°C to about 180°C, or from about 155°C to about 165°C, or about 162°C, and / or an outlet temperature of less than about 150°C, or from about 50°C to about 125°C, or from about 60°C to about 100°C.

67. 60. The method of claim 58, wherein the spray drying is carried out at an inlet temperature greater than about 150°C.

68. 60. The method of claim 58, wherein the spray drying produces the lipase in a yield of greater than about 80%, greater than about 90%, greater than about 95%, or greater than about 99%.

69. 13. The method of any preceding claim, comprising administering a second active agent.

70. 70. The method of claim 69, wherein the second active agent is a fat soluble vitamin, a protease, an amylase, a porcine pancreatic enzyme supplement, a non-porcine lipase, or a combination thereof.

71. 71. The method of claim 70, wherein the fat-soluble vitamin is selected from vitamins A, D, E, K, and combinations thereof.

72. 71. The method of claim 70, wherein the second active agent is pancrelipase, liprotamase, or a combination thereof.

73. The method of any of claims 1 to 72, wherein the patient has acute or chronic pancreatitis.

74. The method of any of claims 1 to 72, wherein the patient has cystic fibrosis.

75. 17. The method of claim 16, wherein the deficiency is caused by pancreatic resection, such as due to pancreatic cancer.

76. 17. The method of claim 16, wherein the deficiency is age-related or due to Shwachman-Diamond syndrome, type 1 diabetes, type 2 diabetes, HIV, celiac disease, or inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).

77. 13. The method of any preceding claim, wherein at least a portion of the lipase is delivered to the duodenum of the patient.

78. 78. The method of claim 77, wherein the portion is at least about 75%.

79. 78. The method of claim 77, wherein the portion is at least about 85%.

80. 78. The method of claim 77, wherein the portion is at least about 95%.

81. 2. A method for increasing fat absorption comprising orally administering to a patient in need thereof a lipase composition.

82. 2. A method for increasing absorption of a fat-soluble vitamin comprising orally administering to a patient in need thereof a lipase composition.

83. 1. A method for treating a patient in need of weight gain, comprising orally administering to a patient in need thereof a lipase composition.

84. 1. A method for treating steatorrhea, comprising orally administering to a patient in need thereof a lipase composition.

85. 1. A method for treating abdominal pain, comprising orally administering to a patient in need thereof a lipase composition.

86. 1. A method for treating flatulence, comprising orally administering to a patient in need thereof a lipase composition.

87. A method for reducing the number of daily bowel movements, comprising orally administering a lipase composition to a patient in need thereof.

88. 13. A method for reducing stool weight comprising orally administering a lipase composition to a patient in need thereof.

89. 1. A method for improving stool form, comprising orally administering a lipase composition to a patient in need thereof.

90. 1. A composition comprising: (a) a lipase; (b) a liquid nutritional formulation.

91. A process for preparing a composition comprising including a lipase in a liquid nutritional formulation.